Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Curevac N.V.
(NQ:
CVAC
)
3.490
+0.010 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,390,096
Open
3.620
Bid (Size)
3.400 (5)
Ask (Size)
3.490 (47)
Prev. Close
3.480
Today's Range
3.410 - 3.980
52wk Range
2.215 - 12.36
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
May 17, 2024
Via
Benzinga
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023
May 15, 2024
CVAC stock results show that CureVac missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-16.71%
-16.71%
1 Month
+35.80%
+35.80%
3 Month
+1.75%
+1.75%
6 Month
-37.57%
-37.57%
1 Year
-60.16%
-60.16%
More News
Read More
3 Stocks to Purge ASAP Before They’re Pulled off Life Support
May 10, 2024
Via
InvestorPlace
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
May 09, 2024
Via
Benzinga
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
November 14, 2023
Via
ACCESSWIRE
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
May 06, 2024
Via
Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
April 24, 2024
Via
ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
April 24, 2024
Via
ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
April 24, 2024
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
April 18, 2024
Via
ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
April 16, 2024
Via
ACCESSWIRE
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
April 12, 2024
Via
Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
April 04, 2024
Via
Benzinga
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
April 04, 2024
Via
ACCESSWIRE
Why Biopharmaceutical Player CureVac Shares Are Rising Today
January 05, 2024
Via
Benzinga
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
January 05, 2024
Via
ACCESSWIRE
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Via
Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
December 19, 2023
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
December 19, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
December 19, 2023
Via
ACCESSWIRE
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
November 15, 2023
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Earnings Scheduled For November 14, 2023
November 14, 2023
Via
Benzinga
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
November 01, 2023
Via
ACCESSWIRE
Why CureVac Stock Plunged Today
September 29, 2023
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.